Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Délais de RDV courts dans la région
105.8 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CH D'AVIGNON HENRI DUFFAUT
305 R RAOUL FOLLEREAU, 84902 AVIGNON CEDEX 9
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Allergy · 2025
ABSTRACT Background Hypereosinophilic syndromes (HES) are a heterogenous group of eosinophilic disorders. To date, only retrospective studies of limited sample‐size and/or follow‐up duration are available. Methods The COHESion study is a national prospective multicenter multidisciplinary cohort recruiting both adults or children with the spectrum of eosinophilic disorders (including reactive HE/HES [HE/HES‐R], idiopathic HES [HES‐I], lymphocytic HES [HES‐L], neoplastic HE/HES [HE/HES‐N], HE of unknown significance [HE‐US], as well as IgG4‐related disease [IgG4RD] or ANCA‐negative eosinophilic granulomatosis with polyangiitis [EGPA] overlaps). Patients are followed‐up yearly. All data about final diagnosis, organ involvement assessments, and outcome profiles in HES‐I were captured and analyzed centrally by HES expert centers. Results From May 2019 to November 2023, 779 patients were included. For this preliminary analysis, 550 cases were available for centralized review (mean ± SD age: 56 ± 18 years, 42% of female patients). The final diagnoses were HES‐I (47%), HE/HES‐R (16%), HE‐US (15%), HE/HES‐N (7%), HE/HES‐L (6%), IgG4RD (2%), and ANCA‐negative EGPA (7%). In the 258 HES‐I patients, outcome profiles were classified as follows: 16.3% had a “single‐flare” without further relapse, 28.3% had a “relapsing–remitting” disease when there was at least a 6‐month period free of symptoms between two flares, 46.1% had a “persistent disease” requiring continuous treatment to avoid relapses (9.3% remained unclassified because of insufficient follow‐up). Conclusions The COHESion cohort is the first nationwide prospective multicenter study collecting data on the full spectrum of HE/HES disorders. This preliminary analysis confirms that idiopathic HES patients have various outcome profiles, suggesting different underlying pathophysiological mechanisms and the need of patient‐specific management. Trial Registration ClinicalTrials.gov identifier: NCT 04018118
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The journal of allergy and clinical immunology. In practice · 2025 · Journal Article
Stammler R, Vallée A, Rohmer J, Grardel N, et al.
Allergy · 2025 · Journal Article
Lefèvre G, Bleuse S, Puyade M, Moulis G, et al.